Astellas has identified neuroscience as a key focus for research and development because of the high unmet needs and tremendous research potential in this therapeutic area. Our efforts in neuroscience straddle both central nervous system disorders and pain therapeutics.

The Central Nervous System Therapeutic Area focuses on treatments in neurology and psychiatry. These diseases and disorders include a wide variety of unrelated conditions with differing origins, such as Alzheimer's disease and schizophrenia. Each of these diseases have serious consequences for the quality of life of millions of patients and their families.

As a global company committed to improving the lives of people around the world with innovative and effective medicines, Astellas is joining the global effort to ease the burden of Alzheimer's disease. Alzheimer's disease is a devastating condition and a growing global health care challenge. Astellas is working to change tomorrow for the patients and families that suffer with Alzheimer's disease. We are developing some treatments that may improve the symptoms of patients, and others that may slow the course or delay the onset of the disease.

Schizophrenia is a similarly difficult condition for patients and their loved ones. Astellas is exploring ways to treat the symptoms of psychosis and cognitive impairment that burden schizophrenic patients. In addition, we are trying to understand more fully the cause of schizophrenia and other psychiatric conditions, which may ultimately lead to new targets and treatments.

The Pain Therapeutic Area is exploring treatments that affect peripheral sensitization, central sensitization and central disinhibition. These therapies may ultimately treat many chronic pain conditions, including neuropathic pain, osteoarthritis, chronic back pain, and fibromyalgia.

By being committed to neuroscience Astellas aims to continue to make a significant and positive difference in the lives of patients.

To learn more about the progress of Astellas' clinical development projects, visit the Overview of R&D Pipeline on the Astellas Pharma Inc. Web site.

Copyright © 2005 - 2009 Astellas Pharma US, Inc.